Cuban scientists from the Center for Genetic Engineering and Biotechnology (CIGB) in Havana test their own therapeutic vaccine against solid tumors, "top priority" of the state group Biocubafarma, which also lists seven other "highly effective" drugs.
"Savax" is the commercial name of the drug, which is in the second phase of testing to check its effectiveness in ovaries and liver tumors, reported the newspaper Juventud Rebelde .
To reach this stage The effect of the vaccine was investigated in a group of 30 patients in advanced stages and "with very limited life expectancy," explained director of biomedical research by CIGB, Gerardo Guillén.
"Almost five years later, not only did the increase in the life of these patients, of which they still live, exist ̵
Next to "Savax" CIGB "serves as a priority" this year in new formulations of Heberprot-P, a successful therapy for treating diabetic foot ulcers and the star project for Cuban biotechnology, registered in more than 20 countries.
A synthetic peptide for the treatment of cardiac ischemia, a drug for rheumatoid arthritis and a treatment for cerebral ischemia.
CIMAVAX-EGF vaccine against lung cancer is published in the history of La Havana Biotechnology and Technology, which also produces "Heberferon" for the treatment of skin cancer and hepatitis B and meningitis vaccines.
The CIGB subsidiary in the province of C Amagüey (center) has also successfully produced Gavac, a vaccine with its own production against cattle fighting.
The biotechnology and pharmaceutical industry's products are among the most important export products in Cuba.